SEC Form IRANNOTICE filed by Novo Nordisk A/S
$NVO
Biotechnology: Pharmaceutical Preparations
Health Care
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
February 5, 2025
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Dear Sirs,
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novo Nordisk A/S has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission on February 5, 2025.
Sincerely,
| /s/ Lars Fruergaard Jørgensen | /s/ Karsten Munk Knudsen | |||||||
Lars Fruergaard Jørgensen President and chief executive officer | Karsten Munk Knudsen Executive vice president and chief financial officer | |||||||